Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial
Background Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM. Method...
Gespeichert in:
| Veröffentlicht in: | International journal of hematology 2021-12, Vol.114 (6), p.653-663 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 663 |
|---|---|
| container_issue | 6 |
| container_start_page | 653 |
| container_title | International journal of hematology |
| container_volume | 114 |
| creator | Suzuki, Kenshi Min, Chang-Ki Kim, Kihyun Lee, Je-Jung Shibayama, Hirohiko Ko, Po-Shen Huang, Shang-Yi Li, Sin-Syue Ding, Bifeng Khurana, Monica Iida, Shinsuke |
| description | Background
Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM.
Methods
Self-identified Asian patients with RRMM (KdD = 46; Kd = 20) with 1‒3 prior therapies were included. The primary endpoint of progression-free survival was estimated by stratified Cox regression.
Results
Baseline demographics and patient characteristics were balanced in both arms. KdD reduced the risk of progression or death by 25% vs Kd [hazard ratio (HR) = 0.75; 95% CI 0.259, 2.168] in the Asian subgroup, compared with 37% vs Kd (0.63; 0.464, 0.854) in the overall CANDOR population. Percentage of patients who reported grade ≥ 3 treatment-emergent adverse events (TEAEs) in the KdD and Kd arms was 95.7 and 90.0%, respectively. Serious AEs were observed in 58.7 and 40.0% of patients in the KdD and Kd arms, respectively. There were two (4.3%) fatal TEAEs in the KdD arm due to infections.
Conclusions
There was a trend toward better efficacy and a favorable benefit-risk profile for KdD vs Kd in Asian patients with RRMM. Cautious interpretation is warranted due to small patient size. |
| doi_str_mv | 10.1007/s12185-021-03204-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2562829964</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2589631562</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-f8d1a8195538396bedab0774bb90aab4b3f916d3a46a5710f96d5fe4ecaa63053</originalsourceid><addsrcrecordid>eNp9kc2O1DAQhC0EYoeFF-CAWuLCYQN2HDsxt9HwK61YCcE5aifOjld2HGxHMDwOT4qHWUDiwKkt9ddVchUhjxl9zihtXyRWs05UtGYV5TVtKnWHbFgnRcXbtrlLNlTVohIto2fkQUo3lLKWNu19csabhlHJxYb82GGcrPsevNUXMJpv6E3eYwqzuQCcRxgxYl796lGDnWGbLM6wYLZmzgm-2ryHaBwuyYwQYnlPEYcc4gH86rJdnAF_MC54fAlLSBn2YYC06usY1qU4oDskmyBMkPcGlmJtgMNu--HV1UfI0aJ7SO5N6JJ5dDvPyec3rz_t3lWXV2_f77aX1cCVytXUjQw7poTgHVdSmxE1LTlorSiibjSfFJMjx0biMZNJyVFMpjEDouRU8HPy7KS7xPBlNSn33qbBOIezCWvqayHrrlZKNgV9-g96E9ZY_nKkOiU5K2yh6hM1xJBSSaZfovUYDz2j_bHB_tRgXxrsfzXYq3L05FZ61d6Mf05-V1YAfgJSWc3XJv71_o_sT7rCqIo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2589631562</pqid></control><display><type>article</type><title>Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Suzuki, Kenshi ; Min, Chang-Ki ; Kim, Kihyun ; Lee, Je-Jung ; Shibayama, Hirohiko ; Ko, Po-Shen ; Huang, Shang-Yi ; Li, Sin-Syue ; Ding, Bifeng ; Khurana, Monica ; Iida, Shinsuke</creator><creatorcontrib>Suzuki, Kenshi ; Min, Chang-Ki ; Kim, Kihyun ; Lee, Je-Jung ; Shibayama, Hirohiko ; Ko, Po-Shen ; Huang, Shang-Yi ; Li, Sin-Syue ; Ding, Bifeng ; Khurana, Monica ; Iida, Shinsuke</creatorcontrib><description>Background
Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM.
Methods
Self-identified Asian patients with RRMM (KdD = 46; Kd = 20) with 1‒3 prior therapies were included. The primary endpoint of progression-free survival was estimated by stratified Cox regression.
Results
Baseline demographics and patient characteristics were balanced in both arms. KdD reduced the risk of progression or death by 25% vs Kd [hazard ratio (HR) = 0.75; 95% CI 0.259, 2.168] in the Asian subgroup, compared with 37% vs Kd (0.63; 0.464, 0.854) in the overall CANDOR population. Percentage of patients who reported grade ≥ 3 treatment-emergent adverse events (TEAEs) in the KdD and Kd arms was 95.7 and 90.0%, respectively. Serious AEs were observed in 58.7 and 40.0% of patients in the KdD and Kd arms, respectively. There were two (4.3%) fatal TEAEs in the KdD arm due to infections.
Conclusions
There was a trend toward better efficacy and a favorable benefit-risk profile for KdD vs Kd in Asian patients with RRMM. Cautious interpretation is warranted due to small patient size.</description><identifier>ISSN: 0925-5710</identifier><identifier>EISSN: 1865-3774</identifier><identifier>DOI: 10.1007/s12185-021-03204-9</identifier><identifier>PMID: 34410635</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Adult ; Adverse events ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - administration & dosage ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Asians ; Demographics ; Demography ; Dexamethasone ; Dexamethasone - administration & dosage ; Drug Resistance, Neoplasm ; Female ; Hematology ; Humans ; Immunotherapy ; Inhibitor drugs ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Multiple myeloma ; Multiple Myeloma - diagnosis ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Oligopeptides - administration & dosage ; Oncology ; Original Article ; Patients ; Prognosis ; Proportional Hazards Models ; Recurrence ; Retreatment ; Risk assessment ; Steroids ; Subgroups ; Targeted cancer therapy ; Treatment Outcome</subject><ispartof>International journal of hematology, 2021-12, Vol.114 (6), p.653-663</ispartof><rights>Japanese Society of Hematology 2021</rights><rights>2021. Japanese Society of Hematology.</rights><rights>Japanese Society of Hematology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-f8d1a8195538396bedab0774bb90aab4b3f916d3a46a5710f96d5fe4ecaa63053</citedby><cites>FETCH-LOGICAL-c399t-f8d1a8195538396bedab0774bb90aab4b3f916d3a46a5710f96d5fe4ecaa63053</cites><orcidid>0000-0001-7132-5337</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12185-021-03204-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12185-021-03204-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34410635$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suzuki, Kenshi</creatorcontrib><creatorcontrib>Min, Chang-Ki</creatorcontrib><creatorcontrib>Kim, Kihyun</creatorcontrib><creatorcontrib>Lee, Je-Jung</creatorcontrib><creatorcontrib>Shibayama, Hirohiko</creatorcontrib><creatorcontrib>Ko, Po-Shen</creatorcontrib><creatorcontrib>Huang, Shang-Yi</creatorcontrib><creatorcontrib>Li, Sin-Syue</creatorcontrib><creatorcontrib>Ding, Bifeng</creatorcontrib><creatorcontrib>Khurana, Monica</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><title>Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial</title><title>International journal of hematology</title><addtitle>Int J Hematol</addtitle><addtitle>Int J Hematol</addtitle><description>Background
Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM.
Methods
Self-identified Asian patients with RRMM (KdD = 46; Kd = 20) with 1‒3 prior therapies were included. The primary endpoint of progression-free survival was estimated by stratified Cox regression.
Results
Baseline demographics and patient characteristics were balanced in both arms. KdD reduced the risk of progression or death by 25% vs Kd [hazard ratio (HR) = 0.75; 95% CI 0.259, 2.168] in the Asian subgroup, compared with 37% vs Kd (0.63; 0.464, 0.854) in the overall CANDOR population. Percentage of patients who reported grade ≥ 3 treatment-emergent adverse events (TEAEs) in the KdD and Kd arms was 95.7 and 90.0%, respectively. Serious AEs were observed in 58.7 and 40.0% of patients in the KdD and Kd arms, respectively. There were two (4.3%) fatal TEAEs in the KdD arm due to infections.
Conclusions
There was a trend toward better efficacy and a favorable benefit-risk profile for KdD vs Kd in Asian patients with RRMM. Cautious interpretation is warranted due to small patient size.</description><subject>Adult</subject><subject>Adverse events</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Asians</subject><subject>Demographics</subject><subject>Demography</subject><subject>Dexamethasone</subject><subject>Dexamethasone - administration & dosage</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Inhibitor drugs</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - diagnosis</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - mortality</subject><subject>Oligopeptides - administration & dosage</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Recurrence</subject><subject>Retreatment</subject><subject>Risk assessment</subject><subject>Steroids</subject><subject>Subgroups</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><issn>0925-5710</issn><issn>1865-3774</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kc2O1DAQhC0EYoeFF-CAWuLCYQN2HDsxt9HwK61YCcE5aifOjld2HGxHMDwOT4qHWUDiwKkt9ddVchUhjxl9zihtXyRWs05UtGYV5TVtKnWHbFgnRcXbtrlLNlTVohIto2fkQUo3lLKWNu19csabhlHJxYb82GGcrPsevNUXMJpv6E3eYwqzuQCcRxgxYl796lGDnWGbLM6wYLZmzgm-2ryHaBwuyYwQYnlPEYcc4gH86rJdnAF_MC54fAlLSBn2YYC06usY1qU4oDskmyBMkPcGlmJtgMNu--HV1UfI0aJ7SO5N6JJ5dDvPyec3rz_t3lWXV2_f77aX1cCVytXUjQw7poTgHVdSmxE1LTlorSiibjSfFJMjx0biMZNJyVFMpjEDouRU8HPy7KS7xPBlNSn33qbBOIezCWvqayHrrlZKNgV9-g96E9ZY_nKkOiU5K2yh6hM1xJBSSaZfovUYDz2j_bHB_tRgXxrsfzXYq3L05FZ61d6Mf05-V1YAfgJSWc3XJv71_o_sT7rCqIo</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Suzuki, Kenshi</creator><creator>Min, Chang-Ki</creator><creator>Kim, Kihyun</creator><creator>Lee, Je-Jung</creator><creator>Shibayama, Hirohiko</creator><creator>Ko, Po-Shen</creator><creator>Huang, Shang-Yi</creator><creator>Li, Sin-Syue</creator><creator>Ding, Bifeng</creator><creator>Khurana, Monica</creator><creator>Iida, Shinsuke</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7132-5337</orcidid></search><sort><creationdate>20211201</creationdate><title>Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial</title><author>Suzuki, Kenshi ; Min, Chang-Ki ; Kim, Kihyun ; Lee, Je-Jung ; Shibayama, Hirohiko ; Ko, Po-Shen ; Huang, Shang-Yi ; Li, Sin-Syue ; Ding, Bifeng ; Khurana, Monica ; Iida, Shinsuke</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-f8d1a8195538396bedab0774bb90aab4b3f916d3a46a5710f96d5fe4ecaa63053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Adverse events</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Asians</topic><topic>Demographics</topic><topic>Demography</topic><topic>Dexamethasone</topic><topic>Dexamethasone - administration & dosage</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Inhibitor drugs</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - diagnosis</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - mortality</topic><topic>Oligopeptides - administration & dosage</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Recurrence</topic><topic>Retreatment</topic><topic>Risk assessment</topic><topic>Steroids</topic><topic>Subgroups</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Kenshi</creatorcontrib><creatorcontrib>Min, Chang-Ki</creatorcontrib><creatorcontrib>Kim, Kihyun</creatorcontrib><creatorcontrib>Lee, Je-Jung</creatorcontrib><creatorcontrib>Shibayama, Hirohiko</creatorcontrib><creatorcontrib>Ko, Po-Shen</creatorcontrib><creatorcontrib>Huang, Shang-Yi</creatorcontrib><creatorcontrib>Li, Sin-Syue</creatorcontrib><creatorcontrib>Ding, Bifeng</creatorcontrib><creatorcontrib>Khurana, Monica</creatorcontrib><creatorcontrib>Iida, Shinsuke</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Kenshi</au><au>Min, Chang-Ki</au><au>Kim, Kihyun</au><au>Lee, Je-Jung</au><au>Shibayama, Hirohiko</au><au>Ko, Po-Shen</au><au>Huang, Shang-Yi</au><au>Li, Sin-Syue</au><au>Ding, Bifeng</au><au>Khurana, Monica</au><au>Iida, Shinsuke</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial</atitle><jtitle>International journal of hematology</jtitle><stitle>Int J Hematol</stitle><addtitle>Int J Hematol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>114</volume><issue>6</issue><spage>653</spage><epage>663</epage><pages>653-663</pages><issn>0925-5710</issn><eissn>1865-3774</eissn><abstract>Background
Due to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM.
Methods
Self-identified Asian patients with RRMM (KdD = 46; Kd = 20) with 1‒3 prior therapies were included. The primary endpoint of progression-free survival was estimated by stratified Cox regression.
Results
Baseline demographics and patient characteristics were balanced in both arms. KdD reduced the risk of progression or death by 25% vs Kd [hazard ratio (HR) = 0.75; 95% CI 0.259, 2.168] in the Asian subgroup, compared with 37% vs Kd (0.63; 0.464, 0.854) in the overall CANDOR population. Percentage of patients who reported grade ≥ 3 treatment-emergent adverse events (TEAEs) in the KdD and Kd arms was 95.7 and 90.0%, respectively. Serious AEs were observed in 58.7 and 40.0% of patients in the KdD and Kd arms, respectively. There were two (4.3%) fatal TEAEs in the KdD arm due to infections.
Conclusions
There was a trend toward better efficacy and a favorable benefit-risk profile for KdD vs Kd in Asian patients with RRMM. Cautious interpretation is warranted due to small patient size.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>34410635</pmid><doi>10.1007/s12185-021-03204-9</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-7132-5337</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0925-5710 |
| ispartof | International journal of hematology, 2021-12, Vol.114 (6), p.653-663 |
| issn | 0925-5710 1865-3774 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2562829964 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Adverse events Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asians Demographics Demography Dexamethasone Dexamethasone - administration & dosage Drug Resistance, Neoplasm Female Hematology Humans Immunotherapy Inhibitor drugs Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - drug therapy Multiple Myeloma - mortality Oligopeptides - administration & dosage Oncology Original Article Patients Prognosis Proportional Hazards Models Recurrence Retreatment Risk assessment Steroids Subgroups Targeted cancer therapy Treatment Outcome |
| title | Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A14%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Carfilzomib,%20dexamethasone,%20and%20daratumumab%20in%20Asian%20patients%20with%20relapsed%20or%20refractory%20multiple%20myeloma:%20post%20hoc%20subgroup%20analysis%20of%20the%20phase%203%20CANDOR%20trial&rft.jtitle=International%20journal%20of%20hematology&rft.au=Suzuki,%20Kenshi&rft.date=2021-12-01&rft.volume=114&rft.issue=6&rft.spage=653&rft.epage=663&rft.pages=653-663&rft.issn=0925-5710&rft.eissn=1865-3774&rft_id=info:doi/10.1007/s12185-021-03204-9&rft_dat=%3Cproquest_cross%3E2589631562%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2589631562&rft_id=info:pmid/34410635&rfr_iscdi=true |